Meyka Pro banner
Alkermes plc

Alkermes plc (ALKS) Stock Overview

Explore Alkermes plc’s financial performance, market position, analyst ratings, and future outlook.

ALKSNASDAQ
HealthcareDrug Manufacturers - Specialty & Generic
$43.39
$2.68(5.82%)
U.S. Market opens in 27h 2m

Alkermes plc (ALKS)

Meyka AI Score

Z

Key Financials

Market Cap7.8B
P/E Ratio109.16
EPS (TTM)$0.95
ROE0.04%
Fundamental Analysis

AI Price Forecasts

1 Month$50.07
3 Months$61.89
1 Year Target$43.98

ALKS Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Alkermes plc (NASDAQ: ALKS) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, Alkermes plc's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of ALKS on the NASDAQ shows an RSI of 29.51, suggesting the stock is in a an oversold condition. Our forecasting models predict a 12-month price target of $43.98 for the NASDAQ listing.

Key metrics behind Alkermes plc's NASDAQ-traded stock include a P/E ratio of 109.16 and a market capitalization of 7.8B. Combined with our AI analysis, these give both institutional and retail investors a clear view of ALKS on the NASDAQ.

Price Performance (NASDAQ: ALKS)

1-Day Change
-7.11%
5-Day Change
-7.19%
1-Month Change
-12.31%
3-Month Change
-3.56%
6-Month Change
59.52%
Year-to-Date (YTD) Change
55.08%
1-Year Change
51.98%
3-Year Change
44.97%
5-Year Change
46.49%
All-Time (Max) Change
688.91%

Contact Information

353 1 772 8000
Connaught House, Dublin, DU, D04 C5Y6

Company Facts

20,500 Employees
IPO DateJul 16, 1991
CountryIE
Actively Trading

Frequently Asked Questions